Altiratinib

阿特替尼

Report date: 2024/07/01 15:40:42
NME

Base Information

Drug NameAltiratinib
Drug Alias Name奥曲替尼DP-5164DCC-2701DCC-22701T-678746713
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsTEK receptor tyrosine kinase antagonistsNerve growth factor receptor Trk-A antagonists +[6] 
TargetsNeurotrophic tyrosine kinase receptor type 3Nerve growth factor receptor Trk-ANeurotrophic tyrosine kinase receptor type 2 +[6] 
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDeciphera Pharmaceuticals Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDeciphera Pharmaceuticals Llc
Active IndicationsN/A
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG